ERBB2 and small cell lung carcinoma: HER2 expression is increased when HER2‐positive SCLC cells acquire chemoresistance, especially CDDP resistance, and the efficacy of NIR‐PIT was significantly higher when SCLC cells acquired CDDP resistance.